Our results indicate a significantly higher prevalence of the CHEK2 Ile157Thr mutation among Finnish patients with advanced NSCLC compared to global, European non‐Finnish, and Finnish populations. The gene discussed is CHEK2; the disease is non-small cell lung carcinoma.